Penny A. Asbell, MD |
Susanne Gardner, PharmD |
Recent work has challenged conventional thinking about the meaning and determinants of antibiotic potency in the ocular situation. In addition, the presence of new topical antibiotic formulations with properties different from other drugs in the class, changes the options available to physicians. By being made aware of these findings, ophthalmologists will be better able to evaluate new medications and select optimal antibiotic agents, especially for surgical prophylaxis.
Rethinking Ocular Antiinfectives will analyze the various factors that determine the efficacy of ocular antibiotics. This discussion will include an overview of how ocular antiinfectives have evolved, and it will offer new thinking about drug penetration into ocular tissues as it relates to antibiotic efficacy. Novel antiinfectives will also be described, as will the impact of the growing prevalence of fluoroquinolone-resistant ocular flora. Ophthalmologists will be able to apply this information immediately as they seek out the best options for preventing and managing ocular infection.
Educational Design
Each installment of Rethinking Ocular Antiinfectives is divided into two parts; each of these parts treats some aspect of the theme in a specific way:
- The "Pharmacology Perspective" is a major review that outlines the expert consensus on the topic area, bringing together the research findings of highly regarded clinical scientists.
- The "Clinical Perspective" takes the information above and applies it to clinical practice from the perspectives of highly qualified ophthalmologists.
Rethinking Ocular Antiinfectives has been produced as an independent Continuing Medical Education enduring material since ©2010, sponsored by Bausch + Lomb.
Faculty: Penny Asbell, MD, & Susanne Gardner, PharmD
View the series: Rethinking Ocular Antiinfectives